Koichi S Kobayashi (Koichi Kobayashi)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

BioEssays : news and reviews in molecular, cellular and developmental biology

Immunogenetics

Nature communications

Hokkaido University

Chiba University School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Hokkaido University Nov 16 2017

Japan

Professor :: Department of Immunology

Texas A&M University Oct 01 2012

United States

Professor :: Microbial Pathogenesis and Immunology

Dana Farber Cancer Institute

United States

Associate Professor :: Cancer Immunology and AIDS

Harvard Medical School

United States

Associate Professor :: Microbiology and Immunology

Harvard Medical School

United States

Assistant Professor :: Pathology

Dana Farber Cancer Institute

United States

Assistant Professor :: Cancer Immunology and AIDS

Yale University School of Medicine

United States

Associate Research Scientist :: Immunobiology

Yale University School of Medicine

United States

Postdoctoral Fellow :: Immunobiology

Education History

Chiba University School of Medicine

Japan

PHD

Publications

Xin Sun, Toshiyuki Watanabe, Yoshitaka Oda, Weidong Shen, Alaa Ahmad, Ryota Ouda, Paul de Figueiredo, Hidemitsu Kitamura, Shinya Tanaka, Koichi S Kobayashi
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Baohui Zhu, Ryota Ouda, Yusuke Kasuga, Paul de Figueiredo, Koichi S Kobayashi
NLRC5/MHC class I transactivator: A key target for immune escape by SARS-CoV-2. BioEssays : news and reviews in molecular, cellular and developmental biology 46 (4) (2024)
Xin Sun, Toshiyuki Watanabe, Yoshitaka Oda, Weidong Shen, Alaa Ahmad, Ryota Ouda, Paul de Figueiredo, Hidemitsu Kitamura, Shinya Tanaka, Koichi S Kobayashi
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Baohui Zhu, Ryota Ouda, Yusuke Kasuga, Paul de Figueiredo, Koichi S Kobayashi
NLRC5/MHC class I transactivator: A key target for immune escape by SARS-CoV-2. BioEssays : news and reviews in molecular, cellular and developmental biology (2024)
Baohui Zhu, Ryota Ouda, Yusuke Kasuga, Paul de Figueiredo, Koichi S Kobayashi
NLRC5/MHC class I transactivator: A key target for immune escape by SARS-CoV-2. BioEssays : news and reviews in molecular, cellular and developmental biology 46 (4) (2024)
Xin Sun, Toshiyuki Watanabe, Yoshitaka Oda, Weidong Shen, Alaa Ahmad, Ryota Ouda, Paul de Figueiredo, Hidemitsu Kitamura, Shinya Tanaka, Koichi S Kobayashi
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Xin Sun, Toshiyuki Watanabe, Yoshitaka Oda, Weidong Shen, Alaa Ahmad, Ryota Ouda, Paul de Figueiredo, Hidemitsu Kitamura, Shinya Tanaka, Koichi S Kobayashi
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Xin Sun, Toshiyuki Watanabe, Yoshitaka Oda, Weidong Shen, Alaa Ahmad, Ryota Ouda, Paul de Figueiredo, Hidemitsu Kitamura, Shinya Tanaka, Koichi S Kobayashi
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Yusuke Kasuga, Ryota Ouda, Masashi Watanabe, Xin Sun, Miki Kimura, Shigetsugu Hatakeyama, Koichi S Kobayashi
FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA. Proceedings of the National Academy of Sciences of the United States of America 120 (24) (2023)
Baohui Zhu, Ryota Ouda, Paul de Figueiredo, Koichi S Kobayashi
ORF6, a repressor of the MHC class I pathway: New molecular target for SARS-CoV-2 drug discovery? Expert opinion on therapeutic targets (2023)
Ying-Shiuan Chen, Jia Li, Sultan Abda Neja, Sabeeta Kapoor, Jorge Enrique Tovar Perez, Chakrapani Tripathi, Rani Menon, Arul Jayaraman, Kyongbum Lee, Wan Mohaiza Dashwood, Shan Wang, Ke Zhang, Koichi S Kobayashi, Praveen Rajendran, Roderick Hugh Dashwood
Metabolomics of Acute vs. Chronic Spinach Intake in an Apc-Mutant Genetic Background: Linoleate and Butanoate Metabolites Targeting HDAC Activity and IFN-γ Signaling. Cells 11 (3) (2022)
Ji-Seung Yoo, Michihito Sasaki, Steven X Cho, Yusuke Kasuga, Baohui Zhu, Ryota Ouda, Hirofumi Sawa, Paul de Figueiredo, Hirofumi Sawa, Koichi S Kobayashi
SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nature communications 12 (1) (2021)
Steven X Cho, Saptha Vijayan, Ji-Seung Yoo, Toshiyuki Watanabe, Ryota Ouda, Ning An, Koichi S Kobayashi
MHC class I transactivator NLRC5 in host immunity, cancer and beyond. Immunology 162 (3) (2020)
Saptha Vijayan, Tabasum Sidiq, Suhail Yousuf, Peter J van den Elsen, Koichi S Kobayashi
Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance. Immunogenetics 71 (3) (2019)

Koichi S Kobayashi.css-eqlu8i{font-size:small;padding-left:4px;} (Koichi Kobayashi)

Publication Activity (10 Years)

Top Topics

Top Venues

Koichi S Kobayashi (Koichi Kobayashi)